Table 2. Patients with either CDR2 or CDR2L antibodies.
| CDR2 | CDR2L | P.cell | CDR2 | |||
| No | Cancer | PNS | IP | IP | IF | LB |
| 1 | Pharynx | Neuropathy | + | − | − | − |
| 2 | Astrocytoma | No | + | − | − | − |
| 3 | Prostate | No | + | − | − | − |
| 4 | Uterus | Unknown | + | − | − | − |
| 5 | Lung | No | + | − | − | − |
| 6 | Breast * | No | + | − | − | − |
| 7 | Breast* | No | + | − | − | − |
| 8 | Colon | Neuropathy | + | − | − | − |
| 9 | Ovary * | No | − | + | − | − |
| 10 | Ovary * | No | − | + | − | − |
| 11 | Ovary * | No | − | + | − | − |
| 12 | Ovary * | No | − | + | − | − |
| 13 | Ovary * | No | − | + | − | − |
| 14 | Breast * | No | − | + | − | − |
| 15 | Breast * | No | − | + | − | − |
*
sera from the breast and ovarian cancer material.
P. cell = Purkinje cell staining.
IP = Immunoprecipitation.
IF = Immunofluorescence.
LB = Line blot.
PNS = Paraneoplastic neurological syndrome.